Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
- Conditions
- Metastatic or Unresectable Solid Tumor Malignancy
- Interventions
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 23
- Registration Number
- NCT01226732
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Oklahoma University, Oklahoma City, Oklahoma, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
- Conditions
- Advanced Cancers
- Interventions
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT01213238
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma
- Conditions
- Ampulla of Vater AdenocarcinomaStage IIIA Ampulla of Vater Cancer AJCC v8Stage IIIB Ampulla of Vater Cancer AJCC v8Stage IIIB Small Intestinal Adenocarcinoma AJCC v8Stage IV Small Intestinal Adenocarcinoma AJCC v8Stage III Ampulla of Vater Cancer AJCC v8Stage III Small Intestinal Adenocarcinoma AJCC v8Stage IV Ampulla of Vater Cancer AJCC v8Stage IIIA Small Intestinal Adenocarcinoma AJCC v8Small Intestinal Adenocarcinoma
- Interventions
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT01208103
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
- Conditions
- Cholangiocarcinoma
- Interventions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT01206049
- Locations
- 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark
Azacitidine and CAPOX in Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01193517
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
- Conditions
- Esophageal CancerGastric Cancer
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT01191697
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2010-08-24
- Lead Sponsor
- Kidney Cancer Research Bureau
- Target Recruit Count
- 51
- Registration Number
- NCT01182142
- Locations
- 🇷🇺
Natalia Petenko, Moscow, Russian Federation
Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2010-07-22
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 60
- Registration Number
- NCT01167049
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 60
- Registration Number
- NCT01167738
- Locations
- 🇮🇹
Istituto Scientifico H. San Raffaele, Milan, Italy
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Biological: bevacizumabBiological: cetuximabDrug: FOLFIRI regimenDrug: FOLFOX regimenDrug: capecitabineDrug: fluorouracilDrug: irinotecan hydrochlorideDrug: leucovorin calciumDrug: oxaliplatinDrug: mitomycin CProcedure: therapeutic conventional surgery
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 340
- Registration Number
- NCT01167725
- Locations
- 🇺🇸
St. Agnes Hospital Cancer Center, Baltimore, Maryland, United States
🇺🇸Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.